

DSM Nutritional Products Denmark ApS

Kirkebjerg Allé 88, 1.
2605 Brøndby
CVR No. 41158158

Annual report 2024

The Annual General Meeting adopted the
annual report on 25.07.2025

DocuSigned by:

Kjeld Kjeldsen

7E28E0452C12481...

Kjeld Raunkjær Kjeldsen

Chairman of the General Meeting

Contents

Entity details	2
Statement by Management	3
Independent auditor's report	4
Management commentary	7
Income statement for 2024	8
Balance sheet at 31.12.2024	9
Statement of changes in equity for 2024	11
Notes	12
Accounting policies	14

Entity details

Entity

DSM Nutritional Products Denmark ApS
Kirkebjerg Allé 88, 1.
2605 Brøndby

Business Registration No.: 41158158
Registered office: Brøndby
Financial year: 01.01.2024 - 31.12.2024

Executive Board

James Young
Kjeld Raunkjær Kjeldsen

Auditors

KPMG
Statsautoriseret Revisionspartnerselskab
Frederiks Plads 42, 7. tv
8000 Aarhus C
CVR No.: 25578198

Statement by Management

The Executive Board has today considered and approved the annual report of DSM Nutritional Products Denmark ApS for the financial year 01.01.2024 - 31.12.2024.

The annual report is presented in accordance with the Danish Financial Statements Act.


In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2024 and of the results of its operations for the financial year 01.01.2024 - 31.12.2024.


We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Brøndby, 25.07.2025

Executive Board

DocuSigned by:

B4FC4956364648C...
James Young

DocuSigned by:

7E28E0452C12481...
Kjeld Raunkjær Kjeldsen

Independent auditor's report

To the shareholder of DSM Nutritional Products Denmark ApS

Opinion

We have audited the financial statements of DSM Nutritional Products Denmark ApS for the financial year 01.01.2024 - 31.12.2024, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2024 and of the results of the Company's operations for the financial year 1 January – 31 December 2024 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter

We draw attention to note 1 to the financial statements setting out that there is an uncertainty as to the measurement of the Company's investments in group enterprises. Our opinion is not modified in respect of this matter.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes

our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Aarhus, 25.07.2025

KPMG

Statsautoriseret Revisionspartnerselskab

CVR No. 25578198

Signed by:




8DDB0522FDD04F7

Katrine Sogaard Gybel

State Authorised Public Accountant

Identification No (MNE) mne45848

Signed by:



D9EFF7A7C2D542D...

Jonas Ellevang Vad

State Authorised Public Accountant

Identification No (MNE) mne50562

Management commentary

Primary activities

The Company's main activity is to own shares in other companies as well as all activities, which at the discretion of the Executive Board, are related to it.

Development in activities and finances

The income statement for 2024 shows a loss of EUR 86 thousand against a loss of EUR 74 thousand last year, and the balance sheet at 31 December 2024 shows equity of EUR 692,753 thousand against an equity of EUR 692,839 thousand last year. Management considers the Company's financial performance in the year satisfactory.

The Company has received a letter of support from the Parent company, DSM Finance B.V, stating that they will provide any necessary financial support to enable the Company to meet its financial obligations. The letter of support is effective for a period of 12 months starting from March 1, 2025.

Uncertainty relating to recognition and measurement

Due to fluctuations in the realized profits comparing to original budgets as part of the purchase of the Glycom entities, management has assessed indications of impairment of investments in group enterprises and impairment indicators are present. Consequently, an impairment test has been performed for the investments in group enterprises, which shows that there is no need for an impairment write-down of recognized investments in group enterprises. The uncertainty regarding measurement for investments in group enterprises exists, as revenue and earnings of the CGU must increase to support the recognized carrying value of the investments group enterprises based on higher sales to existing customers and successful launch in the world largest HMO market China.

Management refers to note 1 for a more detailed description of the main assumptions used in the impairment test and the related uncertainty.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Income statement for 2024

	Notes	2024 EUR'000	2023 EUR'000
Gross profit/loss		(4)	(2)
Other financial expenses	2	(107)	(93)
Profit/loss before tax		(111)	(95)
Tax on profit/loss for the year		25	21
Profit/loss for the year		(86)	(74)
Proposed distribution of profit and loss			
Retained earnings		(86)	(74)
Proposed distribution of profit and loss		(86)	(74)

Balance sheet at 31.12.2024

Assets

	Notes	2024 EUR'000	2023 EUR'000
Investments in group enterprises		694,969	694,969
Financial assets		694,969	694,969
Fixed assets		694,969	694,969
Receivables from group enterprises		0	11
Joint taxation contribution receivable		56	21
Receivables		56	32
Cash		0	4
Current assets		56	36
Assets		695,025	695,005

Equity and liabilities

	Notes	2024 EUR'000	2023 EUR'000
Contributed capital		100	100
Retained earnings		692,653	692,739
Equity		692,753	692,839
Trade payables		4	0
Payables to group enterprises		2,268	2,166
Current liabilities other than provisions		2,272	2,166
Liabilities other than provisions		2,272	2,166
Equity and liabilities		695,025	695,005

Uncertainty relating to recognition and measurement	1
Employees	3
Contingent liabilities	4
Group relations	5

Statement of changes in equity for 2024

	Contributed capital EUR'000	Retained earnings EUR'000	Total EUR'000
Equity beginning of year	100	692,739	692,839
Profit/loss for the year	0	(86)	(86)
Equity end of year	100	692,653	692,753

Notes

1 Uncertainty relating to recognition and measurement

The investments in group enterprises pertain to the acquisition of Glycom A/S and its subsidiaries in April 2020. There is uncertainty regarding the measurement of these investments, as the recognized carrying amount depends on an increase in revenue and earnings from the cash-generating unit (CGU). This anticipated growth is based on assumptions of higher sales to existing customers and the successful full launch in the world largest HMO market China.

Due to the fluctuation in results of group enterprises, Management has assessed that there are indications of impairment. Consequently, an impairment test has been performed to determine if the value in use of the intangibles exceeds the carrying value

The impairment test did not show any need for impairment write-down. The basis for the impairment test has been a discounted cash flow model based on the following assumptions:

- Discounted cash flow forecasts derived from the most recent budgets/forecasts for the next ten years (2025 through 2033) approved by Management.
- The budgets/forecasts show an expected revenue increase in the coming years (compound average annual growth rate over the next 9 years of 13%).
- The budgets/forecasts show an expected increase in operating margin (average annual increase in operating margin of 5 percentage points per year over the next nine years).
- The valuation model and the discounted cash flows are supported by an assessed WACC of 7.2%.

The sensitivity of a potential write-down on intangible assets is primary related to the Company's fulfillment of the derived budgets/forecasts, including budgeted income statement, balance sheet and cash flows for 2025-2033. Furthermore, sensitivity is related to underlying strategic actions and value drivers where we are dependent on a successful launch in the worlds largest HMO marked China and continuous growth on 3rd party sales is important strategic targets to be met and continued collaboration with critical business partners on 3rd party sales. Based on the development and results met already in these initiatives, and the general dynamics in the HMO market we feel confident to meet the targets to fulfill the assumptions made in the impairment test. We have received the necessary approval from the Chinese authorities and are currently working on the last steps towards launching in China and 3rd party partner has approved continued collaboration in 2025 and has committed to continue in 2026, approval is expected during 2025.

Together with the financial support confirmed by DSM Finance B.V of group enterprises, the Management expects to be able to carry out its plans in the coming year and therefore realize the budgets and forecasts used in the impairment trigger analysis.

2 Other financial expenses

	2024	2023
	EUR'000	EUR'000
Financial expenses from group enterprises	104	90
Other financial expenses	3	3
	107	93

3 Employees

The Entity has no employees other than the Executive Board. The Executive Officer has not received any remuneration.

4 Contingent liabilities

The Entity participates in a Danish joint taxation arrangement where DSM Nutritional Products A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore liable for income taxes etc. for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed entities.

5 Group relations

DSM Nutritional Products Denmark ApS is part of the consolidated financial statements of DSM B.V., Wilhelminasingel 39, 6221 BE, Maastricht, The Netherlands, which is the smallest group, in which the Company is included as a subsidiary.

Copies of the consolidated financial statements of DSM B.V. may be ordered at the following address:
DSM B.V., Wilhelminasingel 39, 6221 BE, Maastricht, The Netherlands.

Accounting policies

Reporting class

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C.

Consolidated financial statements

Referring to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements have been prepared.

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables, payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.

Income statement

Gross loss

Other external expenses have been aggregated into one item in the income statement named gross loss in accordance with section 32 of the Danish Financial Statements Act.

Other external costs

Other external expenses comprise administrative expenses etc.

Financial expenses

Financial expenses comprise interest expense, financial costs regarding gains and losses on receivables, payables and transactions denominated in foreign currencies, etc.

Tax on loss for the year

Tax for the year comprises current tax for the year. The tax expense relating to the loss for the year is recognised in the income statement at the amount attributable to the loss for the year and directly in equity at the amount attributable to entries directly in equity.

The Entity is jointly taxed with all Danish group enterprises. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

Balance sheet

Investments

Investments in group enterprises are measured at cost. In case of indication of impairment, an impairment test is conducted. When the cost exceeds the recoverable amount, write-down is made to this lower value.

The carrying amount of investments in group enterprises is subject to an annual test for indications of impairment. Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may be impaired. Write-down is made to the recoverable amount if this is lower than the carrying amount.

Receivables

Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.

Joint taxation contributions receivable or payable

Current tax receivable is recognised in the balance sheet as tax computed on the taxable income for the year.

The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

Cash at bank and in hand

Cash at bank and in hand comprise cash and deposits.

Liabilities other than provisions

Liabilities are measured at amortised cost, which usually corresponds to nominal value.